

Free Paper Session

Friday, May 30, 2025



1. Hepato-Biliary and Pancreas Surgery

15:10-16:20		Yang-Seok Koh (Chonnam National Univ.), Sae Byeol Choi (Korea Univ.)
FP-1 15:10-15:20	Development and External Validation of an Online Risk Calculator for Early Mortality after Hepatic Resection in HCC	Han Liu (First Hospital of Jilin Univ., China)
FP-2 15:20-15:30	Role of Hepatobiliary Scintigraphy in Predicting Post-Hepatectomy Liver Failure: A Single-Center Cohort Study	Jeong-Moo Lee (Seoul National Univ.)
FP-3 15:30-15:40	Preoperative Risk Stratification in Hilar Cholangiocarcinoma Using a Novel Decision Tree Model	Han Liu (First Hospital of Jilin Univ., China)
FP-4 15:40-15:50	Medical Conflicts and Their Effect on Korean Liver-Related Publications: A 2019–2024 Analysis	Namkee Oh (Sungkyunkwan Univ.)
FP-5 15:50-16:00	The Role of Neoadjuvant Chemotherapy (nCT) in the Treatment of Patients with Resectable Pancreatic Cancer	Vervekin Ilya (Pavlov First Saint Petersburg State Medical Univ., Russia)
FP-6 16:00-16:10	Innovative Artificial Intelligence and Machine Learning Based Spatial Computing AR Navigation for Open, Lap, and Robotic Hepatectomy	Takuya Sueyoshi (Teikyo Univ., Japan)
FP-7 16:10-16:20	An Evaluation of Long-Term Fasting Effects on Preoperative and Postoperative Outcomes in Liver Surgery	Rosinta Hotmaida Pebrianti Purba (The Pranala Institute, Indonesia)

2. Liver Cancer, Clinical 1

15:10-16:30		Do Young Kim (Yonsei Univ.), In Hye Song (Univ. of Ulsan)
FP-8 15:10-15:20	Prognostic Impact of Tumor-Associated Endothelial B7-H3 Expression in HCC	Yunmi Ko (Seoul National Univ.)
FP-9 15:20-15:30	Non-Contrast Magnetic Resonance Imaging versus Ultrasonography for HCC Surveillance: A Randomized, Single-Center Trial	Hyungjin Rhee (Yonsei Univ.)

2. Liver Cancer, Clinical 1

FP-10 15:30-15:40	Outcomes by Transarterial Chemoembolization (TACE) Modality from Participants (pts) with Embolization-Eligible Hepatocellular Carcinoma (HCC) Treated with Durvalumab (D) + Bevacizumab (B) + TACE and Placebos (PBO) + TACE: EMERALD-1 Subgroup Analysis <i>Jeong Heo (Pusan National Univ.)</i>
FP-11 15:40-15:50	Clinical Utility of Circulating Tumor DNA in Early-Stage Biliary Tract Cancer Following Curative Resection <i>James Yu (H. Lee Moffitt Cancer Center, USA)</i>
FP-12 15:50-16:00	Early Changes in Neutrophil-to-Lymphocyte Ratio as a Prognostic Marker for Tumor Response to Atezolizumab and Bevacizumab in HCC: A Multicenter Retrospective Study <i>Young Mi Hong (Pusan National Univ.)</i>
FP-13 16:00-16:10	Comparative Efficacy of Lenvatinib versus Sorafenib as Sequential Therapies Following Atezolizumab and Bevacizumab Treatment in Advanced HCC: A Multicenter Retrospective Study <i>Jun Sik Yoon (Pusan National Univ.)</i>
FP-14 16:10-16:20	Risk of Variceal Bleeding in Patients Receiving Atezolizumab–Bevacizumab Treatment for HCC <i>Won-Mook Choi (Univ. of Ulsan)</i>
FP-15 16:20-16:30	Indeterminate Nodule-Like Arterial Phase Hyperenhancement in the Liver on CT: Differentiation of HCCs from Vascular Pseudolesions Using a CT Radiomics Approach <i>Ijin Joo (Seoul National Univ.)</i>

3. MASLD, Clinical

15:10-16:30 <i>Byung Ik Kim (Sungkyunkwan Univ.), Won-Choong Choi (Eulji Univ.)</i>	
FP-16 15:10-15:20	Metabolic Dysfunction-Associated Fibrosis 5 (MAF-5) Score and the Risk of Liver-Related Events in the General Population <i>Byeong Geun Song (Sungkyunkwan Univ.)</i>
FP-17 15:20-15:30	Cost-Effectiveness Analysis of Masld Screening Using FIB-4 Based Two-Step Algorithm in the Medical Check-up <i>Hye-Lin Kim (Sahmyook Univ.)</i>

3. MASLD, Clinical

FP-18 15:30-15:40	The Prognostic Impact of Statin Exposure in Metabolic Dysfunction-Associated Steatotic Liver Disease <i>Keungmo Yang (The Catholic Univ. of Korea)</i>
FP-19 15:40-15:50	Influence of Skeletal Muscle Loss on CKD Development in Metabolic Dysfunction-Associated Steatotic Liver Disease Patients <i>Aryoung Kim (Inje Univ.)</i>
FP-20 15:50-16:00	Risk of Liver-Related Events in Metabolic Dysfunction-Associated Steatotic Liver Disease: Impact of Cardiometabolic Risk Factor Count and Its Longitudinal Changes <i>Han Ah Lee (Chung-Ang Univ.)</i>
FP-21 16:00-16:10	Impact of Steatotic Liver Disease and Metabolic Risk Factors on Post-Surgical Outcomes in HBV-Related HCC <i>Younghyeon Ahn (Univ. of Ulsan)</i>
FP-22 16:10-16:20	Allyl Nonanoate: A Bile Metabolite and Potential Biomarker for Hepatic Fibrosis in MASLD <i>Soo Hyeon Lee (Hanyang Univ.)</i>

4. HBV Basic & ALD

15:10-16:30		<i>Chul Ju Han (Korea Cancer Center Hospital), Soon Woo Nam (The Catholic Univ. of Korea)</i>
FP-23 15:10-15:20	Misclassification of Alcohol Use Disorder in MASLD and MetALD: Prevalence, Clinical Characteristics, and Outcomes <i>Hyo Young Lee (Hanyang Univ.)</i>	
FP-24 15:20-15:30	Circulating Fungal Mycobiome and Lipid Dysregulation Induces Mitochondrial Dysfunction Mediated Shock in Severe Alcoholic Hepatitis <i>Gaurav Tripathi (ILBS, India)</i>	
FP-25 15:30-15:40	Impact of Gastrectomy on the Risk of Alcohol-Related Liver Disease: A Nationwide Population-Based Cohort Study in Korea <i>Sang Yi Moon (Dong-A Univ.)</i>	
FP-26 15:40-15:50	Intrahepatic IgA Accumulation Activates Macrophages and Exacerbates Hepatic Inflammation in Alcoholic Liver Disease <i>Min Gu Kim (The Catholic Univ. of Korea)</i>	

4. HBV Basic & ALD

FP-27 15:50-16:00	Circulating HBcrAg Levels Reflect Transcriptionally Active cccDNA and Predict Advanced Fibrosis in HBeAg-Negative Inactive Carriers <i>Hye Seon Kim (The Catholic Univ. of Korea)</i>
FP-28 16:00-16:10	HBV Core Antigen and Impaired Placental Immunity: A Key Driver of HBV Entry Receptor Expression <i>Ashish Kumar Vyas (Amrita Research Center Delhi NCR, India)</i>
FP-29 16:10-16:20	Chronic Hepatitis B Genotype C Mouse Model with Persistent Covalently Closed Circular DNA <i>Deok Hwa Seo (The Catholic Univ. of Korea)</i>
FP-30 16:20-16:30	Thiazole-Coumarin-Azomethine Derivatives as Dual TLR7/STING Agonists for Innate Immune Activation in Chronic Hepatitis B: Computational Design and Pharmacokinetic Profiling <i>Rizki Rachmad Saputra (Universitas Palangka Raya, Indonesia)</i>

5. Acute Liver Failure & DILI

15:10-16:30 <i>Suk Bae Kim (Dankook Univ.), Seung Kak Shin (Gachon Univ.)</i>	
FP-31 15:10-15:20	TRAIP Alleviates DDC-Induced Cholestatic Liver Injury through Modulating PI3K/Akt/mTOR Signaling <i>Gangping Feng (Guangxi Medical Univ., China)</i>
FP-32 15:20-15:30	NOX2 Is a Promising Target against Acute Liver Injury by Reversing Oxidative Stress, Mitochondrial Dysfunction and cGAS-STING Pathway-Dictated Inflammatory Response <i>Chao Sun (Tianjin Medical Univ., China)</i>
FP-33 15:30-15:40	Plasma Derived Exosomes Multi-Omics Analysis Classifies Bacterial Peptide and Metabolomic Cargo as Predictor of Early Mortality in Acute Liver Failure <i>Neha Sharma (Institute of Liver and Biliary Sciences, India)</i>
FP-34 15:40-15:50	Genetic Polymorphism Analysis That Associated with Metabolism and Idiopathic Pathway of Antituberculosis Drug Induced Liver Injury <i>Putrya Hawa (Indonesian Defense Univ., Indonesia)</i>

5. Acute Liver Failure & DILI

FP-35 15:50-16:00	N-Acetylcysteine Reduces Mortality and Length of Stay in Adult with Non-Acetaminophen-Induced Acute Liver Failure: Evidence from a Meta-Analysis <i>Agil Noviar Alvirosa (Muhammadiyah Lamongan Hospital, Indonesia)</i>
FP-36 16:00-16:10	Elevated Plasma Chenodeoxycholic Acid as a Prognostic Marker and Therapeutic Target in Acute Liver Failure: Role of Bacteroides Intestinalis AM1 Intervention in Bile Acid Modulation and Mitigation of Liver Injury <i>Sushmita Pandey (Institute of Liver and Biliary Sciences, India)</i>
FP-37 16:10-16:20	Gallic Acid-Loaded Gold Nanoparticles Prevent High Fat Diet-Induced Non-Alcoholic Fatty Liver Disease via Modulating Endoplasmic Reticulum, ATF6/AMPK/PPAR α /p-eIF2 α Levels, and the NF- κ B/SMAD-4 Protein Expression <i>Deepika Singh (SIHAS, SHUATS, India)</i>
FP-38 16:20-16:30	Quantum Chemical Features Meet Clinical Data for DILI Prediction: Integrating Electronic Density Distribution of Antibiotics with Patient EMR Data <i>Seongbin Kim (Handong Global Univ.)</i>

6. HBV 1

15:10-16:30 Yun Soo Kim (Gachon Univ.), Sung Jae Park (Inje Univ.)	
FP-39 15:10-15:20	Inverted U-Shaped Association between Hepatitis B Core-Related Antigen and HCC Incidence in Patients with Chronic Hepatitis B <i>Ji Eun Han (Ajou Univ.)</i>
FP-40 15:20-15:30	Tenofovir Alafenamide vs. Tenofovir Disoproxil Fumarate in Lowering the Risk of HCC Development in Patients with Chronic Hepatitis B: A Propensity Scores Matching Analysis <i>Seong Hee Kang (Korea Univ.)</i>
FP-41 15:30-15:40	HCC Risk in Treatment-Naïve Chronic Hepatitis B Patients Treated with Tenofovir Alafenamide or Tenofovir Disoproxil Fumarate: A Korean Nationwide Study <i>Jiwon Yang (Univ. of Ulsan)</i>
FP-42 15:40-15:50	Superior Efficacy of Besifovir in Reducing HCC Risk Compared to Tenofovir in CHB Patients: A Nationwide Cohort Study <i>Yoon E Shin (Soonchunhyang Univ.)</i>

6. HBV 1

FP-43 15:50-16:00	E-Cigarette Use and HCC Risk in Patients with Chronic Hepatitis B <i>Byeong Geun Song (Sungkyunkwan Univ.)</i>
FP-44 16:00-16:10	Prediction of Long-Term HBsAg Seroclearance in HBeAg-Negative Chronic Hepatitis B Patients <i>Hae Lim Lee (The Catholic Univ. of Korea)</i>
FP-45 16:10-16:20	Kinetics of Hepatitis B Surface Antigen Loss Following 8 Years of Tenofovir-Based Treatment with Chronic Hepatitis B <i>Jeong Heo (Pusan National Univ.)</i>
FP-46 16:20-16:30	Incidence and Risk of Controlled Attenuated Parameter-Based Non-Alcoholic Hepatosteatosis Development in Korean Patients with Chronic Hepatitis B <i>Ye-Rin Chae (Yonsei Univ.)</i>

7. Liver Cancer, Basic

15:10-16:30 <i>Ji Hoon Kim (Korea Univ.), Haeryoung Kim (Seoul National Univ.)</i>	
FP-47 15:10-15:20	Aggressiveness-Promoting, Fibroblast Activation Protein-STAT3 Positive Feedback Loop Is Activated by IL-6 in Cancer Associated Fibroblasts of HCC <i>Deok Hwa Seo (The Catholic Univ. of Korea)</i>
FP-48 15:20-15:30	Significance of Shelterin Component TPP1 Upregulation and Telomerase Activation in the Clinico-Pathological Features of HCC <i>Jung Eun Jang (The Catholic Univ. of Korea)</i>
FP-49 15:30-15:40	AK7 Drives HCC Progression by Enhancing Stemness, EMT, and Hypoxia Adaptation <i>Geum Ok Baek (Ajou Univ.)</i>
FP-50 15:40-15:50	NADPH Oxidase 2 Regulates Epithelial-Mesenchymal Transition Signaling via Sterol Regulatory Element-Binding Protein 2 and Promotes HCC Survival <i>Hei-Gwon Choi (Chungnam National Univ.)</i>
FP-51 15:50-16:00	Diagnostic and Prognostic Impact of Circulating Exosome microRNA for the Early Stage of HBV Induced HCC <i>HyoJu Kim (Soonchunhyang Univ.)</i>

7. Liver Cancer, Basic

FP-52 16:00-16:10	Investigation for Prognostic Value of Circulating Tumor DNA by Serum KMT2B Gene and Fragmentation Analysis for the Hbv-Derived HCC after Curative Resection <i>Sung Hwan Yoo (Yonsei Univ.)</i>
FP-53 16:10-16:20	Identification of Novel Links between Cirrhosis and HCC through Mechanisms of Immune Microenvironment <i>Eunjeong Kim (Kyungpook National Univ.)</i>
FP-54 16:20-16:30	Association between Gut Microbial Dynamics and Clinical Outcomes in Patients with HCC Receiving Chemoembolization: A Prospective Study <i>Jiwon Yang (Univ. of Ulsan)</i>



Free Paper Session

Saturday, May 31, 2025

8. Liver Cancer, Clinical 2

13:10-14:30		Jin-Young Choi (Yonsei Univ.), Sang Min Yoon (Univ. of Ulsan)
FP-55 13:10-13:20	A Machine Learning Model to Predict the Treatment Response of Atezolizumab plus Bevacizumab in Patients with HCC Incorporating Computed Tomogram-Derived Imaging Biomarkers	<i>Moon Haeng Hur (Seoul National Univ.)</i>
FP-56 13:20-13:30	Association of Survival with Discordance between Preoperative Radiology and Postoperative Pathology in Patients with HCC	<i>Woo Sun Rou (Chungnam National Univ.)</i>
FP-57 13:30-13:40	Differential Therapeutic Effectiveness of Atezolizumab plus Bevacizumab in Unresectable HCC Based on Chronic Hepatitis B Viral Activity and Etiology: A Multicenter Cohort Study	<i>Yunmi Ko (Seoul National Univ.)</i>
FP-58 13:40-13:50	Identification of Plasma Protein Biomarkers for Predicting Response to Atezolizumab-Bevacizumab in Unresectable HCC	<i>Myung Ji Goh (Sungkyunkwan Univ.)</i>
FP-59 13:50-14:00	Efficacy and Safety of Sorafenib as a Later-Line Treatment in Advanced HCC: A Phase 2 Study	<i>Yongsu Park (National Cancer Center)</i>
FP-60 14:00-14:10	Can an Ai Predictive Model Be Integrated into Clinical Decision-Making for Predicting Open Conversion in Minimally Invasive Liver Resection?	<i>Boram Lee (Seoul National Univ.)</i>
FP-61 14:10-14:20	Comparison of Treatment Efficacy and Safety Profile of Atezolizumab plus Bevacizumab in BCLC B and C Patients with HCC	<i>Sun Young Chun (Chonnam National Univ.)</i>
FP-62 14:20-14:30	Radiofrequency Ablation versus Minimally Invasive Liver Resection for Small Solitary HCC (3cm) with MRI Features for Predicting Microvascular Invasion	<i>Na Reum Kim (Yonsei Univ.)</i>

9. HBV 2

13:10-14:30

Hyung Joon Kim (Chung-Ang Univ.), Jung Il Lee (Yonsei Univ.)

FP-63 13:10-13:20	X/Precore Mutational Complexity and Its Impact on HBV Replicative Activity and Histological Progression in HBeAg-Positive Chronic Hepatitis B <i>Jae Mo Han (The Catholic Univ. of Korea)</i>
FP-64 13:20-13:30	Prevalence of Viral Hepatitis B, D, and C among Adolescent and Adult Mongolian Migrants in Seoul, Korea: Implications for Early Screening and Intervention <i>Wonseok Kang (Sungkyunkwan Univ.)</i>
FP-65 13:30-13:40	Antiviral Therapy Reduces Dyslipidemia and Cardiovascular Risk in Chronic Hepatitis B: TDF as the Most Effective Agent <i>Hyuk Kim (Soonchunhyang Univ.)</i>
FP-66 13:40-13:50	Efficacy and Safety of Switching Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in Chronic Hepatitis B Patients with Multidrug Resistance <i>Jaehong Jeong (Yonsei Univ.)</i>
FP-67 13:50-14:00	Comparing Liver Disease Severity and Comorbidity in Patients with HBV Mono-Infection and HBV/HDV Co-Infection: A Korean Nationwide Population-Based Study <i>Heejoon Jang (Seoul National Univ.)</i>
FP-68 14:00-14:10	The Clinical Characteristics among HBV and HDV Co-Infected Mongolian Patients <i>Oyungerel Lkhagva-Ochir (Liver Center, Mongolia)</i>
FP-69 14:10-14:20	An Artificial Intelligence Model Utilizing Imaging Biomarkers on Computed Tomogram to Predict HCC in Patients with Chronic Hepatitis B <i>Hyunjae Shin (Seoul National Univ.)</i>
FP-70 14:20-14:30	Seroprevalence and Clinical Characteristics of Hepatitis D Virus Infection in Korean Patients with Chronic Hepatitis B, Liver Cirrhosis, and HCC <i>Eun Sun Jang (Seoul National Univ.)</i>

10. HCV

13:10-14:30		Won Hyeok Choe (Konkuk Univ.), Geum-Youn Gwak (Sungkyunkwan Univ.)
FP-71 13:10-13:20	Changes in Healthcare Costs of Hepatitis C Patients after Introduction of Direct-Acting Antivirals (DAAs) in Korea	Hwa Young Choi (National Cancer Center)
FP-72 13:20-13:30	Cost-Effectiveness of Direct Acting-Antivirals for Chronic Hepatitis C in South Korea	Won Sohn (Sungkyunkwan Univ.)
FP-73 13:30-13:40	Advanced Fibrosis and Cardiometabolic Risk Burden Increase Atherosclerotic Cardiovascular Events in Chronic Hepatitis C Patients with Steatotic Liver Disease after Viral Eradication	Ming-Lung Yu (Kaohsiung Medical Univ., Taiwan)
FP-74 13:40-13:50	Association between Hepatitis C Virus Infection and Cardiovascular Disease: A Nationwide, Population-Based Cohort Study in South Korea	Min Kyung Park (Seoul National Univ.)
FP-75 13:50-14:00	Long-Term HCC Development Following Sustained Virologic Response in Korean Chronic Hepatitis C Patients Treated with Direct Acting Antivirals	Eunho Choi (Korea Univ.)
FP-76 14:00-14:10	Real-World Outcomes of Sofosbuvir/Velpatasvir in a Variety of Hepatitis C Patient Populations: A Retrospective Cohort Study	Young Joo Park (Pusan National Univ.)
FP-77 14:10-14:20	Chrono-Optimal Treatments for HIV/HCV Co-Infection Yield Comparable Survival Outcomes with HCV Mono-Infection	Jeayeon Park (Seoul National Univ.)
FP-78 14:20-14:30	Study of Safety and Efficacy of Ledipasvir + Sofosbuvir in HCV Infection in Pregnancy: A Real-Life Experience	Jatinkumar Veljibhai Dhanani (GMERS Medical College, India)

11. MASLD, LC & Others, Basic

13:10-14:30

Youngmi Jung (Pusan National Univ.), Eun Young Cho (Wonkwang Univ.)

FP-79 13:10-13:20	Identification of Prognostic Factors and Regulatory Pathways in Porto-Sinusoidal Vascular Disorder <i>Won-Mook Choi (Univ. of Ulsan)</i>
FP-80 13:20-13:30	A Novel 11 β -HSD1 Inhibitor Ameliorates Liver Fibrosis by Inhibiting the Notch Signaling Pathway and Increasing NK Cell Population <i>Ji Eun Kim (Hanyang Univ.)</i>
FP-81 13:30-13:40	FiNi-Seq: A Quasi-Spatial Single-Cell Transcriptome Based on Physical Properties Defines Early Damage Niche of the Liver <i>Kwon Yong Tak (KAIST)</i>
FP-82 13:40-13:50	Spatial Transcriptomics Reveals TAZ Signalling-Mediated Regulation of Liver Fibrosis in MASH <i>Young-Sun Lee (Korea Univ.)</i>
FP-83 13:50-14:00	Nintedanib Alleviates Metabolic Dysfunction-Associated Steatohepatitis by Suppressing THBS1 Expression in Activated Fibroblasts <i>Sung Woo Cho (The Catholic Univ. of Korea)</i>
FP-84 14:00-14:10	Targeting CD47 by Engineered Stem Cell-Derived SIRP α -Extracellular Vesicles Ameliorates Liver Fibrosis via Macrophage Reprogramming <i>Yoon Kyoung Kim (SHIFTBIO)</i>
FP-85 14:10-14:20	PNPLA3 I148M GG Variant Driven Immune Cell Infiltration Associates with Metabolic Dysfunction-Associated Steatotic Liver Disease Progression <i>Jung Hoon Cha (The Catholic Univ. of Korea)</i>
FP-86 14:20-14:30	Investigating the Induction Mechanism of the Initial Aging Microenvironment in the Liver through Single-Cell Multi-Omics Analysis <i>Seoyeong Lee (KAIST)</i>

12. Liver Transplantation 1

13:10-14:30		Young Seok Han (Daegu Catholic Univ.), Bo-Hyun Jung (Inje Univ.)
FP-87 13:10-13:20	An Increase in Regulatory B Cells Plays a Crucial Role in Achieving Tolerance in Liver Transplantation Patients	Soon Kyu Lee (<i>The Catholic Univ. of Korea</i>)
FP-88 13:20-13:30	Ferulic Acid-Loaded Liposomes Mitigate Hepatic Ischemia-Reperfusion Injury in a Rat Model Associated with Liver Transplantation via Altering Apoptosis, Mitochondrial Function and TLR-4/NF-B/NLRP3 Inflammatory Pathway	Deepika Singh (<i>SIHAS, SHUATS, India</i>)
FP-89 13:30-13:40	Feasibility of Simultaneous Splenectomy in ABO Incompatible Living Donor Liver Transplantation with Small-for-Size Graft	JaRyung Han (<i>Daegu Catholic Univ.</i>)
FP-90 13:40-13:50	The Impact of Everolimus Use on Incisional Hernia in Liver Transplant Patients	Eunjin Lee (<i>Sungkyunkwan Univ.</i>)
FP-91 13:50-14:00	Transcriptomic Profiling of Personalized Immunosuppressant Modelling to Prevent Acute Cellular Rejection (ACR) in Pediatric Liver Transplant Recipients	Anindya Amanda Damayanti (<i>Islamic Indonesia Univ., Indonesia</i>)
FP-92 14:00-14:10	Safety of Living Right Liver Donors Aged 45 and Older: Risks and Outcomes for Donors and Recipients	Sang-Hoon Kim (<i>Univ. of Ulsan</i>)
FP-93 14:10-14:20	Adult-to-Adult Right Lobe Graft Living Donor Liver Transplantation for Acute-on-Chronic Liver Failure: A Single-Centre Retrospective Study in Vietnam	The Duy Nguyen (<i>Vin Univ., Vietnam</i>)
FP-94 14:20-14:30	Quality Score : Development of Integrative Prognostic Index for Living Donor Liver Using Multicentric Registry Data	Mun Chae Choi (<i>Armed Forces Capital Hospital</i>)

13. Liver Transplantation 2

13:10-14:30*Doojin Kim (Gachon Univ.), Sangho Bae (Soonchunhyang Univ.)*

FP-95 13:10-13:20	Severity and Pattern of Bile Duct Complications after Donor Right Hepatectomy: Open versus Minimally Invasive Approaches <i>Na Reum Kim (Yonsei Univ.)</i>
FP-96 13:20-13:30	Prognostic Concordance between LI-RADS Imaging and Pathology for Liver Transplant Eligibility in HCC: Results from 1,059 Patients <i>Yeongseok Hwang (Univ. of Ulsan)</i>
FP-97 13:30-13:40	Aging in Place for Elderly Undergo Liver Transplantation: How Informal Care Could Help Maintaining Higher Quality of Life? <i>Hepri Ardianson (The Pranala Institute, Indonesia)</i>
FP-98 13:40-13:50	Development and Optimization of Transplant Surgeon-Innovated Evmp: Validation in a Porcine DCD Liver Transplant Model <i>Mun Chae Choi (Armed Forces Capital Hospital)</i>
FP-99 13:50-14:00	Prediction Of Early Risk of Patient Survival Following Liver Transplant Based on Lifestyle Factors via Machine Learning Models <i>Manvendra Singh (HMFA MIET, India)</i>
FP-100 14:00-14:10	Development of Immune-Evasive Meta-Soft Organ Modules through Advanced Cell Engineering and Assembly Technology <i>Hee Ju Kim (Hanyang Univ.)</i>
FP-101 14:10-14:20	Rehabilitation for Fatigue after Liver Transplantation: Effects of Exercise and Physical Activity Counseling <i>Ganesh Kumar Singh (Army Forced Hospital, Nepal)</i>
FP-102 14:20-14:30	Clinical Outcomes of 90 Cases of Post-Transplant Lymphoproliferative Disorder (PTLD) after Liver Transplantation: A 24-Years Single- Center Experience <i>Young-In Yoon (Univ. of Ulsan)</i>